The central premise of the study is that macrophages and monocytes inside tumors exist in a continuum of functional states that cannot be reduced to a single binary. To quantify this continuum, the researchers built the MDRi around three core programs: an injury program capturing stress responses such as iron and heme handling, hypoxia, inflammatory chemokines and danger-sensing pathways; a resolution program reflecting tissue repair, efferocytosis, lipid processing and resident-like macrophage biology; and a combined antigen-presentation and interferon program, abbreviated APC/IFN, that brings together major histocompatibility complex activity and interferon-stimulated genes. From the injury and resolution programs they also derived an injury-resolution axis, a single metric that places each cell along a spectrum from active damage to active healing.

Constructing and validating a framework of this kind required an unusually broad evidence base. The team established MDRi in an immune checkpoint blockade-treated multi-cancer atlas containing 47,750 myeloid cells drawn from 192 samples spanning eight cancer types. They then tested the framework separately in an independent multi-cancer myeloid dataset to confirm that the identified programs were not artifacts of a particular cohort or sequencing batch. Because the antigen-presentation and interferon-response gene sets were deliberately constructed to be non-overlapping, agreement between these two signatures provided gene-independent support for the validity of the APC/IFN dimension, an important safeguard against circular reasoning in signature-based immunology.

One of the more technically interesting aspects of the study concerns the geometry of myeloid cell states. Using trajectory inference, the researchers found that macrophage and monocyte states organized along related but non-identical functional dimensions, and root-sensitivity analyses revealed a subtle but important caveat: the connectivity of the states was stable regardless of where the trajectory was anchored, but the inferred directionality of pseudotime depended on the choice of root. The authors interpret this as evidence that MDRi captures genuine transcriptional topology rather than a universal developmental sequence, a deliberately cautious conclusion that resists over-interpreting pseudotime as a maturation timeline in tumor myeloid biology.

The framework was then put to the test against clinical data. In exploratory analyses of checkpoint blockade-treated patients, the researchers observed that post-treatment non-responders showed concurrent elevation of injury, resolution and APC/IFN scores, suggesting a globally activated but functionally ambivalent myeloid compartment. However, when the analyses were adjusted for cancer type and treatment regimen, the data did not support an independent predictive effect of MDRi scores on response. Complementary analyses of T and natural killer cells indicated that immune differences associated with treatment response were actually more evident in pretreatment samples, hinting that the pretreatment immune landscape, rather than treatment-induced myeloid changes, may carry the stronger predictive signal.

Prognostic analysis in bulk tumor data added another layer of context dependence. The researchers projected MDRi programs onto patient-level cohorts from The Cancer Genome Atlas and fitted joint multivariable Cox models containing the injury, resolution and APC/IFN scores. The derived injury-resolution axis was excluded from these joint models because it is mathematically dependent on its two components, a statistically transparent choice. The results showed MDR injury acting as an adverse factor in selected cancers, while resolution and APC/IFN displayed associations that varied by cancer type and clinical endpoint. In other words, the same myeloid program can be associated with better outcomes in one tumor type and worse outcomes in another, which is precisely the kind of context dependence the framework was designed to expose.

Because single-cell atlases are far less common than bulk transcriptomic cohorts, a framework is only as useful as its portability. The researchers benchmarked MDRi against established immune-deconvolution methods such as MCP-counter, TIMER and xCell, as well as against published tumor-associated macrophage signatures. The comparison demonstrated partial but non-uniform overlap, meaning that MDRi captures myeloid-state information that is related to, but not fully explained by, conventional deconvolution scores. This positions the index as a complementary rather than redundant measurement, adding functional granularity that abundance-based methods cannot provide.

The spatial dimension of myeloid biology received particular attention. Using Visium spatial transcriptomics in nasopharyngeal carcinoma, the team mapped MDRi programs onto hematoxylin and eosin stained tissue sections, revealing that injury, resolution and APC/IFN programs occupy focal tissue niches rather than being uniformly distributed. A parallel multi-cancer Xenium analysis at single-cell spatial resolution across cervical cancer, glioblastoma, lung cancer and melanoma further revealed platform- and cancer-dependent spatial distributions of the MDRi-related programs, including cancer-specific estimates of how APC/IFN-high myeloid cells position themselves near tumor cells and how checkpoint interactions vary in their vicinity. These findings suggest that the functional identity of myeloid cells is shaped not only by cancer type but by precise anatomical microenvironment.

To make the framework accessible, the researchers released MDRi Explorer, an open-source Shiny application that implements scoring, reference comparison, survival analysis and benchmark visualization. Users can apply MDRi to their own transcriptomic data, compare their results against built-in references, and explore cancer-specific score distributions and survival associations from TCGA. The authors are careful to frame the contribution appropriately: MDRi is presented as a reusable, hypothesis-generating framework for investigating context-dependent myeloid functional organization, not as a universal prognostic signature or a clinically validated predictor. That restraint is notable in a field where signature-based tools are often oversold.

The broader significance of the work lies in its refusal to flatten myeloid biology into a single number. By decomposing the tumor myeloid compartment into injury, resolution and antigen-presentation/interferon dimensions, and by documenting honestly where those dimensions matter, where they do not, and how their meaning shifts across cancers, platforms and treatment settings, the study provides the immunology community with a map that is as much about uncertainty as about discovery. For researchers designing myeloid-targeted therapies, the message is that the same cell population may be a friend in one tumor and an enemy in another, and that any intervention must be interpreted against the local context of tissue damage, repair and antigen presentation.

Subject of Research: A single-cell-derived myeloid damage response index quantifying context-dependent myeloid functional states across cancers

Article Title: A single-cell-informed framework maps context-dependent myeloid damage-response states across cancers

Article References: Ding, R., Zheng, W., Long, Z., Cao, Z., Liang, J., & Quan, Q. (2026). A single-cell-informed framework maps context-dependent myeloid damage-response states across cancers. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04543-4

Image Credits: AI Generated

DOI: 10.1007/s00262-026-04543-4

Keywords: tumor-associated macrophages, myeloid cells, single-cell RNA sequencing, spatial transcriptomics, pan-cancer, immune checkpoint blockade, immune deconvolution, antigen presentation, interferon signaling, TCGA, myeloid damage response index, tumor microenvironment

The commentary, written by Rama Ayyala of Cincinnati Children’s Hospital Medical Center and the University of Cincinnati Medical Center, proposes a framework for wellness-centered leadership that reframes leadership itself as a primary wellness intervention. Its central premise is drawn from a growing body of evidence: burnout is driven less by deficiencies in individual resilience than by chronic workplace stressors, including excessive workload, inefficient workflows, staffing shortages, communication failures, and organizational culture. If that is true, then the people with the most influence over those conditions are not wellness officers offering yoga classes, but the department chairs, medical directors, and team leads who design the daily work environment.

The scale of the problem in pediatric imaging is well documented. Previous surveys of the Society for Pediatric Radiology have found substantial burnout prevalence among pediatric radiologists, alongside identifiable stressors ranging from workload to administrative burden. The specialty faces a paradox familiar across medicine: professionals describe their work as highly rewarding, citing meaningful patient interactions, multidisciplinary collaboration, teaching, mentorship, and research, while simultaneously reporting symptoms of exhaustion and disengagement. Imaging volume and complexity continue to climb, demanding greater subspecialized knowledge and faster, more accurate interpretations. The author describes this as a growing functional burden, one that extends beyond raw case counts to encompass the mental effort of synthesizing complex clinical information, communicating findings, and making high-stakes decisions under time pressure.

Operational friction compounds the cognitive load. Inappropriate or unclear imaging requests, competing clinical priorities, and frequent interruptions create inefficiencies that frustrate physicians, technologists, and nursing staff alike. Workforce shortages force individuals to meet rising demands with fewer resources, and caring for critically ill children adds a significant element of emotional labor. Crucially, the commentary emphasizes that these stressors do not erase the meaning of the work; fulfillment and stress can coexist, and clinicians can remain deeply engaged while experiencing significant burnout symptoms. That distinction matters because it shifts the diagnosis: burnout may reflect not a lack of meaning or personal grit, but systems that erect unnecessary barriers to meaningful work.

This is where the critique of conventional wellness programs becomes sharp. The author argues that many organizational initiatives amount to what has been called performative wellness, or carewashing: pizza parties, resilience workshops, meditation sessions, and wellness newsletters that create the appearance of institutional concern while leaving the structural drivers of distress untouched. Worse, such programs can subtly transfer responsibility for coping onto individuals, implying that those who struggle simply lack resilience. This framing risks stigmatizing distressed employees and discouraging honest conversations about workplace problems. Decades of occupational psychology research, including the influential work of Christina Maslach and colleagues, points instead to chronic mismatches between job demands and available resources, lack of control over work, and toxic organizational cultures as the true engines of burnout.

The proposed alternative is a three-pillar framework for wellness-centered leadership, adapted from work by Tait Shanafelt and colleagues at Stanford. The first pillar is caring about people. Leaders build trust by deliberately fostering psychological safety, the shared belief that employees can speak up, ask questions, report concerns, and admit mistakes without fear of embarrassment or punishment. That requires consistent humility, transparency, curiosity, and visible follow-up on feedback, not just invitations to share ideas. Behaviors such as active listening, transparent communication during change, recognition and gratitude, stay interviews, and leaders modeling healthy work-life boundaries all reinforce the message that employees matter. The familiar observation that people leave leaders rather than organizations, the author suggests, is a warning worth heeding.

The second pillar is cultivating relationships. Pediatric radiology depends on a diverse team of physicians, technologists, nurses, child life specialists, administrators, researchers, IT professionals, and trainees, and community across those silos does not develop automatically. Leaders must engineer opportunities for connection through inclusive decision-making, multidisciplinary workgroups, shared quality initiatives, mentorship, and cross-professional recognition. Remote and hybrid work adds friction, reducing informal interaction and professional visibility, so leaders must ensure that visibility reflects contribution rather than physical presence and that access to information, recognition, and development opportunities is equitable regardless of work location. Shared purpose is protective as well: prior research shows that physicians who spend at least 20 percent of their professional effort on the activities they find most meaningful experience substantially lower burnout, giving leaders a concrete lever for fulfillment.

The third pillar, and arguably the hardest, is inspiring change by fixing the work itself. Even without new staff or budgets, leaders can target modifiable sources of distress: inappropriate STAT requests, inefficient workflows, unnecessary administrative tasks, scheduling inequities, and communication failures. Engaging frontline teams to identify low-value work, simplify processes, and clarify priorities turns prioritization into a core leadership responsibility. Expanding imaging access into evenings and weekends supports patient-centered care but risks overburdening a constrained workforce unless staffing and interpretation capacity expand in parallel. The author argues that operational excellence should be treated as an essential wellness strategy, and that when problems cannot be solved, transparent communication about limitations and meaningful employee involvement in decisions can preserve trust.

Measurement is the thread that ties the framework together. Departments rigorously track turnaround time, productivity, quality, and patient experience, yet rarely measure employee well-being with the same discipline. The commentary calls for professional fulfillment, psychological safety, trust, workplace inclusion, and retention risk to be added to routine departmental dashboards alongside traditional metrics, with repeated climate and pulse surveys to monitor progress. Measurement, however, must be the beginning of improvement, not the end: surveys without visible action erode trust and discourage future participation. For leaders unsure where to start, the commentary offers a practical roadmap: ask employees directly what makes their work harder than it should be, hold role-specific listening sessions, fix one operational pain point to build credibility with a small win, follow up visibly and transparently, and protect time for meaningful work while recognizing contributions across every professional role.

The ultimate message is blunt and, for many healthcare organizations, uncomfortable. The goal is not to make healthcare professionals more resilient to broken systems but to build better systems that support the people who provide care. Leadership, the author concludes, is not adjacent to workforce well-being; it is the intervention itself. In a field where burnout is increasingly understood as an organizational disease rather than a personal failing, the departments that thrive will be those whose leaders shape culture, foster community, dismantle unnecessary barriers, and treat the employee experience with the same rigor they apply to any clinical metric. For the children and families who depend on pediatric imaging, the sustainability of that workforce may be one of the most consequential health interventions of all.

Subject of Research: Wellness-centered leadership as an organizational intervention to reduce burnout in pediatric radiology

Article Title: Empowering leaders, empowering teams: fostering wellness through leadership

Article References: Ayyala, R. (2026). Empowering leaders, empowering teams: fostering wellness through leadership. Pediatric Radiology. https://doi.org/10.1007/s00247-026-06774-0

Image Credits: AI Generated

DOI: 10.1007/s00247-026-06774-0

Keywords: burnout, leadership, pediatric radiology, physician wellness, psychological safety, organizational culture, workforce retention, healthcare leadership, professional fulfillment, wellness-centered leadership, workplace stress, employee experience

The review, conducted by researchers at Shiraz University of Medical Sciences, Tehran University of Medical Sciences and University College London, followed the PRISMA 2020 guidelines and searched PubMed, Scopus, Web of Science and Embase for studies published up to September 2025. The team’s protocol was prospectively registered in the PROSPERO database. From the initial search, twenty-four preclinical studies met the inclusion criteria: animal models in which investigators assessed distant tumor regression or systemic immune activation following PDT, whether delivered alone or in combination with other therapies.

The findings were strikingly consistent. Across the included studies, PDT reliably produced local tumor regression and activated the immune system, with the molecular fingerprints of immunogenic cell death clearly visible. Dying tumor cells released damage-associated molecular patterns, exposed calreticulin on their surfaces, and recruited cytotoxic CD8-positive T lymphocytes into the tumor microenvironment. These are the same hallmarks that immunologists look for when a cell death event is capable of training the adaptive immune system to recognize and attack cancer, rather than simply clearing debris.

The abscopal effect itself, named from ‘ab’ meaning away and ‘scopal’ meaning target, has historically been a rare and unpredictable curiosity in radiation oncology. When it occurs, a localized treatment appears to prime immune cells that then travel through the circulation and attack tumors that were never irradiated. For decades, clinicians reported it only sporadically, and its rarity made it difficult to study. The new review suggests that PDT may offer a more controllable way to induce this systemic response, because the therapy’s oxidative burst can be tuned by adjusting drug dose, light intensity, timing and photosensitizer chemistry.

Crucially, the strongest abscopal responses emerged when PDT was paired with immune checkpoint blockade, specifically antibodies targeting programmed cell death protein-1, or PD-1, and its ligand PD-L1. Checkpoint inhibitors release the molecular brakes that tumors place on T cells, and the review’s authors found that combining them with PDT’s immune-priming effect produced clear distant tumor regression in several animal studies. Adjuvants, substances that boost immune signaling, also amplified the systemic response when co-administered with the light treatment. This synergy makes mechanistic sense: PDT floods the tumor with antigens and danger signals, while checkpoint blockade ensures the newly activated T cells are not silenced as they circulate.

The systemic nature of the immune activation was confirmed at the molecular level. Multiple studies reported upregulation of key inflammatory cytokines, including interleukin-6, interferon-gamma and tumor necrosis factor-alpha, in the circulation of treated animals. These signaling molecules are characteristic of a robust, body-wide immune response rather than a purely local inflammatory reaction. Interferon-gamma in particular is central to antitumor immunity, enhancing antigen presentation and directly inhibiting tumor cell proliferation, while tumor necrosis factor-alpha contributes to vascular disruption within tumors and supports cytotoxic lymphocyte function.

What distinguishes PDT from radiotherapy, its closest conceptual rival for abscopal induction, is the nature of the cell death it provokes. Reactive oxygen species generated by the photosensitizer can trigger immunogenic apoptosis and necrosis while preserving tumor antigen integrity, and PDT can also damage tumor vasculature and reprogram the immunosuppressive tumor microenvironment. The review notes that immune reprogramming, the shift of a tumor from a cold, T-cell-excluded state to a hot, inflamed state, appears to be a key mechanism by which PDT converts a local treatment into a systemic one. By depleting suppressive myeloid cells and regulatory T cells and promoting dendritic cell maturation, PDT can create the conditions under which newly primed T cells can function effectively.

The authors are careful to frame their conclusions as preclinical, with early clinical studies offering preliminary support but not definitive proof. Animal models of cancer frequently overstate immune effects that later fail to translate into human trials, and the twenty-four studies included in the review varied in photosensitizer, tumor model, light dosing and combination regimens, making direct comparison difficult. The review nonetheless argues that the consistency of the immune activation signals across models, and the reproducibility of abscopal responses when PDT is combined with checkpoint blockade, justify moving the field toward carefully designed clinical evaluation. Optimizing treatment parameters, the authors suggest, may allow PDT to evolve from a local, cytotoxic treatment into a genuine systemic cancer immunotherapy.

The implications for patients with metastatic disease are considerable. If a clinician could illuminate a single accessible lesion and thereby vaccinate the patient’s immune system against their own tumor, the strategy could complement existing immunotherapies rather than replace them. Combination trials pairing PDT with PD-1 or PD-L1 inhibitors are the most obvious next step, and the review’s systematic synthesis of preclinical evidence provides a roadmap for which parameters, photosensitizers and adjuvant strategies appear most promising. Questions remain about the durability of the induced immunity, the risk of immune-related adverse events, and whether human tumors, which are more heterogeneous than laboratory models, will respond as predictably.

For now, the review stands as the most comprehensive preclinical assessment to date of PDT’s ability to reach beyond the beam of light that delivers it. It documents a therapy long thought of as surgically precise quietly revealing a second identity: an immune catalyst capable of sending signals far beyond the treated site. As the authors conclude, with optimized parameters and rational combinations with immunotherapy, photodynamic therapy may develop from a local cytotoxic tool into a systemic weapon against cancer, one that turns a single illuminated tumor into the trigger for a body-wide immune campaign.

Subject of Research: Systematic review of preclinical evidence that photodynamic therapy induces immunogenic cell death and abscopal, systemic antitumor immune responses

Article Title: Immunogenic and systemic antitumor responses induced by photodynamic therapy: a systematic review of the abscopal effect

Article References: Faghani-Eskandarkolaei, P., Zareei-khooshab, V., Mansouri-Bidekani, R., Heli, H., Abdollahi, M., Haghighi, H., Zahraie, N., & Sattarahmady, N. (2026). Immunogenic and systemic antitumor responses induced by photodynamic therapy: a systematic review of the abscopal effect. Cancer Cell International. https://doi.org/10.1186/s12935-026-04455-4

Image Credits: AI Generated

DOI: 10.1186/s12935-026-04455-4

Keywords: photodynamic therapy, abscopal effect, immunogenic cell death, reactive oxygen species, immune checkpoint blockade, CD8-positive T lymphocytes, calreticulin, damage-associated molecular patterns, cytokines, tumor microenvironment, cancer immunotherapy, metastatic cancer

The clinical backdrop explains why the innovation matters. Pancreatic ductal adenocarcinoma, the most common and most lethal form of pancreatic cancer, has seen its five-year overall survival improve from roughly 4 percent to 13 percent over recent decades, according to data cited in the report. Yet the prognosis remains poor, and typical presentations include weight loss, jaundice, abdominal pain, new or worsening diabetes, and steatorrhea, the fatty stools that signal impaired digestion. Tumors of the pancreatic head sit in a crowded anatomical neighborhood, wrapped around the portomesenteric venous confluence where the splenic and superior mesenteric veins merge into the portal vein. As the tumor grows, it can compress or invade these vessels, producing portal hypertension, fluid accumulation in the abdomen known as ascites, and swelling of the bowel wall that interferes with nutrition. Under European Society for Medical Oncology guidelines, contrast-enhanced computed tomography is the mainstay of diagnosis, mapping tumor size, vascular involvement, and metastatic spread, while biopsy is indicated before chemotherapy, with endoscopic ultrasound-guided fine-needle biopsy preferred over CT-guided approaches.

The patient in the report arrived with a four-month history of weight loss, mild steatorrhoea, and newly developed ascites. Imaging revealed a mass in the pancreatic head that encased both the superior mesenteric vein and the superior mesenteric artery, obstructed the portomesenteric venous confluence, and had spawned a network of venous collaterals alongside thickening of the bowel wall, particularly the duodenum. Apposing thrombus, or clot, was also present within the affected veins. He was judged ineligible for surgery, making a tissue diagnosis essential before palliative chemotherapy could begin. The first endoscopic ultrasound-guided biopsy attempt had to be abandoned because interposed collateral vessels blocked a safe needle path. A second attempt returned tissue that showed only signs of chronic pancreatitis, an inconclusive result that left the team without proof of malignancy and the patient without access to cancer treatment.

At this point the multidisciplinary team chose a dual-purpose intervention. To relieve the ascites and bowel oedema, they planned a transjugular portosystemic shunt with portal vein recanalization, an approach abbreviated PVR-TIPS. In a standard TIPS procedure, a track is created through the liver connecting the hepatic vein to the portal vein, shunting blood to decompress the portal system. Here, the team extended the concept: after creating the shunt under fluoroscopic guidance, they passed catheters and guidewires through the blocked portomesenteric venous confluence and advanced them into the superior mesenteric vein, reopening the obstructed venous highway from within. This recanalization simultaneously created a working channel that led directly past the tumor-bearing portion of the pancreatic head.

What followed was the technically novel step. Because there was still no histological proof of cancer, the team decided to sample the tumor through the vein they had just reopened. An 8 French gastroscope biopsy forceps, an instrument normally used inside the stomach, was pushed under fluoroscopic guidance through the 10 French TIPS sheath and advanced into the tumor-bearing segment of the pancreatic head. Three tissue samples were obtained from inside the vessel. The interventional sequence was then completed with the placement of a 12-millimeter bare metal stent across the externally compressed venous segment, restoring flow through the portomesenteric confluence. The clinical response was rapid: bowel oedema resolved within hours, ascites decreased markedly within four weeks, and histology confirmed pancreatic ductal adenocarcinoma. Palliative chemotherapy was initiated just one week after the procedure.

The report situates this case within a growing but still limited literature on venous decompression in pancreatic cancer. Transhepatic portomesenteric venous stenting is already an established palliative treatment for locally advanced disease. In the largest published series, covering 129 patients of whom 119 had pancreatic cancer, technical success reached 97 percent with only four adverse events, and at 20 months of follow-up primary stent patency was 80 percent, with symptom relief in most patients. A separate series of 40 pancreatic cancer patients treated with direct percutaneous transhepatic portomesenteric venous stenting showed that the approach can do more than relieve symptoms: it enabled patients with tumor thrombus in the portal vein to receive chemotherapy, and 15 of the 40 went on to undergo the Whipple procedure, the complex surgical removal of the pancreatic head, without vascular resection.

Biopsy through blood vessels, by contrast, has a narrower track record. Non-targeted transvenous biopsies are routine for diffuse liver and kidney disease, but targeted transvenous sampling of specific lesions remains rare. Where it has been used, operators typically combine fluoroscopy with intravascular ultrasound for image guidance, and studies suggest the technique is valuable precisely for targets that lack a safe percutaneous window, the corridor of tissue a needle must cross to reach a lesion without injuring vessels or organs. Previous intraportal approaches have been percutaneous rather than transjugular: one recent report described a percutaneous transhepatic portal access using gastroscope biopsy forceps to biopsy portal vein invasion by a pancreatic neuroendocrine tumor, and a similar transhepatic route has been used in hepatocellular carcinoma with tumor thrombus. A transbiliary route, passing instruments through the bile ducts, has also been described for sampling inaccessible pancreatic head masses, though it is equally uncommon.

The transjugular route described in the new report offers distinct advantages. Because the shunt and stenting were performed anyway for palliative decompression, the biopsy added no separate access route, allowing venous decompression and histological confirmation to be accomplished in one sitting. The authors also argue that an endovascular transportal approach may reduce the inherent bleeding risk compared with percutaneous or endoscopic ultrasound-guided biopsy, in the same way that transjugular liver and kidney biopsies are favored in coagulopathic patients, since any bleeding occurs into the vessel itself rather than into the peritoneal cavity. Nevertheless, the technique is not without hazards: vessel injury remains a concern, and adjunct imaging such as cone-beam computed tomography is recommended to minimize damage to non-target structures and to improve sample quality. The single-case nature of the evidence means broader safety and efficacy data will be needed before the approach enters routine practice.

Even so, the case signals a meaningful expansion of the interventional toolkit for pancreatic cancer, a disease in which the window for effective treatment is often agonizingly narrow. For patients whose tumors are wrapped in collateral vessels, whose clot or anatomy blocks standard needle paths, or whose earlier biopsies returned falsely reassuring inflammation, the ability to combine shunt creation, vein recanalization, stenting, and tumor sampling through a single transjugular access could shorten the path from obstruction to diagnosis to chemotherapy. The report’s conclusion is measured but clear: endovascular transportal biopsy is a feasible method for obtaining histopathological diagnosis in pancreatic head tumors, even after failed endoscopic ultrasound-guided biopsy, and it can be seamlessly combined with other interventional measures such as portal vein recanalization and stenting. As interventional oncology continues to blur the line between diagnosis and treatment, this vein-borne route to one of medicine’s hardest-to-reach tumors may find a growing role.

Subject of Research: Endovascular transportal biopsy of pancreatic head tumors via the portal vein prior to stenting

Article Title: Transportal endovascular biopsy prior to portal vein stenting in pancreatic cancer

Article References: Mahnken, A. H. (2026). Transportal endovascular biopsy prior to portal vein stenting in pancreatic cancer. CVIR Oncology, 2(1), Article 12. https://doi.org/10.1007/s44343-026-00046-2

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00046-2

Keywords: pancreatic cancer, endovascular biopsy, portal vein stenting, transjugular portosystemic shunt, interventional radiology, pancreatic ductal adenocarcinoma, portal vein recanalization, endoscopic ultrasound, ascites, venous decompression, biopsy techniques, palliative care

The study, led by Emily L. Podany and Andrew A. Davis of Washington University in St. Louis together with collaborators at Weill Cornell Medicine, Northwestern University, and Massachusetts General Hospital, drew on clinical and genomic data collected between 2015 and 2024. All patients had metastatic breast cancer and had undergone liquid biopsy testing with the Guardant360 assay, which detects mutations, copy number changes, and gene fusions across dozens of cancer-related genes from a simple blood sample. To quantify neighborhood disadvantage, the team used the Area Deprivation Index, or ADI, a validated composite of seventeen measures including poverty, employment, and education, ranked nationally from 1 to 100 by nine-digit zip code. Patients scoring 60 or above were classified as living in high deprivation neighborhoods.

Of the 1,127 patients analyzed, 335, or 29.7 percent, lived in high deprivation areas. Black patients were more than three times as likely as White patients to reside in these neighborhoods, reflecting the deep entanglement of race and socioeconomic disadvantage in the United States. After adjusting for age, race, cancer subtype, sites of metastatic disease, treatment line, and other clinical variables, the researchers found that patients from high deprivation neighborhoods had roughly 49 percent higher odds of harboring TP53 mutations in their tumors. Conversely, they were significantly less likely to carry AKT1 mutations, an alteration typically enriched in slower-growing, lower-grade luminal tumors.

The TP53 gene encodes p53, often described as the guardian of the genome. In healthy cells, this tumor suppressor protein halts division when DNA is damaged, triggers repair mechanisms, and pushes irreparably damaged cells into programmed death. When TP53 is mutated, that safety net collapses, allowing abnormal cells to proliferate unchecked. Mutations in the gene appear in roughly 30 percent of breast cancers and are linked to higher tumor grade, more aggressive subtypes, and worse prognosis. The new findings echo earlier tissue-based studies that connected household income and socioeconomic deprivation to higher p53 mutation frequency, but they extend that evidence to a large, racially diverse cohort of metastatic patients using blood-based genomic profiling.

Intriguingly, patients in high deprivation neighborhoods were less likely to present with visceral, lymph node, or soft tissue metastases, which might ordinarily suggest less advanced disease. Yet their survival was shorter. The authors propose that TP53-mutated tumors may drive rapid, aggressive progression even at lower disease burden, potentially before the kind of metastatic crises that prompt urgent intervention. They also point to the compounding weight of social determinants of health: patients in deprived neighborhoods experience higher rates of food insecurity, sarcopenia, and chronic disease, all of which erode the physical resilience needed to tolerate intensive cancer treatment.

The study also uncovered a stark treatment gap. Among 136 patients with hormone receptor-positive, HER2-negative metastatic disease who carried activating PIK3CA mutations and were therefore eligible for PI3K inhibitor therapy, only 17.4 percent of those in high deprivation neighborhoods actually received the drugs, compared with 36.7 percent of patients in low deprivation areas. This disparity emerged despite equal rates of PIK3CA mutations across deprivation groups, meaning the biological eligibility for targeted therapy was the same. The gap points squarely at access, not biology, as the limiting factor.

PI3K inhibitors such as alpelisib, approved by the Food and Drug Administration in 2019, and related AKT pathway inhibitors such as capivasertib represent some of the most consequential advances in precision oncology for breast cancer. But these therapies are expensive, require genomic testing to identify eligible mutations, and are often available primarily at academic cancer centers concentrated in affluent regions. Prior research has shown that patients from disadvantaged neighborhoods travel longer distances for care, are less likely to enroll in clinical trials, more often lack private insurance, and experience longer treatment delays and higher rates of therapy discontinuation. The new data suggest these structural barriers now extend into the era of molecularly targeted medicine.

Survival differences were perhaps the most sobering result. Median overall survival from the time of circulating tumor DNA testing was 24 months for patients in high deprivation neighborhoods versus 28 months for those in low deprivation areas, a statistically significant difference. When the researchers stratified by race, the picture became even more stark: Black patients in high deprivation neighborhoods survived a median of just 15 months, compared with 25 months for Black patients in low deprivation areas and 28 months for White patients regardless of neighborhood. Notably, Black patients living in advantaged neighborhoods fared as well as White patients, indicating that neighborhood deprivation and race interact to produce the worst outcomes rather than race acting alone.

The authors caution that the study has limitations. All patients were treated at large academic medical centers, so the findings may not generalize to community hospitals or rural clinics. The Area Deprivation Index has been criticized for overemphasizing housing values, and a single time-point measure cannot capture the cumulative environmental exposures involved in carcinogenesis, which unfolds over years or decades. Because the analysis was exploratory, no correction for multiple statistical testing was applied. Still, the cohort’s geographic breadth, spanning catchment areas across multiple states, and its use of individual-level chart review and uniform genomic testing lend considerable strength to the conclusions.

The implications reach beyond oncology. If living in a deprived neighborhood is associated with a distinct mutational landscape in metastatic tumors, then environmental stressors, chronic inflammation, and social adversity may be biologically embedded in cancer in ways that precision medicine alone cannot undo. The research team calls for laboratory studies of environmental exposures, epidemiological work on molecular subtypes by deprivation, and implementation science aimed at dismantling barriers to targeted therapy access. The team also plans structured patient interviews to understand precisely why eligible patients in high deprivation areas miss out on PI3K inhibitors. In the meantime, the study stands as a molecular argument that zip code should not determine tumor biology, treatment, or survival, and that closing the gap will require intervening on the neighborhoods themselves, not just the cancers within them.

Subject of Research: Associations between neighborhood deprivation and breast cancer tumor genomics, targeted treatment use, and survival in metastatic breast cancer patients

Article Title: Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival

Article References: Podany, E. L., Foffano, L., Gerratana, L., Medford, A. J., Heater, N. K., Nicolò, E., Tapiavala, S., Pontolillo, L., Putur, A., Jaber, D. A., Clifton, K., Katakam, N., Addison, S., Lipsyc-Sharf, M., Reduzzi, C., Ademuyiwa, F. O., Puglisi, F., Gradishar, W. J., Ma, C. X., … Davis, A. A. (2026). Associations of neighborhood deprivation with breast cancer tumor genomics, targeted treatment use, and survival. Breast Cancer Research and Treatment, 219(2), Article 5. https://doi.org/10.1007/s10549-026-08068-3

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08068-3

Keywords: breast cancer, neighborhood deprivation, Area Deprivation Index, TP53, circulating tumor DNA, PI3K inhibitors, health disparities, precision oncology, metastatic breast cancer, survival, social determinants of health, liquid biopsy

Mast cell tumours are the most frequently diagnosed cutaneous malignancy in dogs, accounting for an estimated 16 to 21 percent of all skin neoplasms. They arise from mast cells, immune cells rich in inflammatory mediators such as histamine and heparin, and typically present as masses in the skin or the tissue beneath it. Their biological behaviour spans an extraordinary range: some are cured permanently by simple surgical excision, while others ulcerate, recur locally and spread to lymph nodes, liver and spleen. Paraneoplastic effects driven by the release of mast cell granules can produce itching, bruising, skin swelling and gastrointestinal signs, complicating the clinical picture. Two histological grading systems, the three-tier Patnaik scheme and the two-tier Kiupel scheme, are widely used to predict behaviour, and both have been shown to be consistently prognostic, particularly when applied together.

Golden Retrievers have repeatedly been identified as a breed at increased risk of MCTs, and germline genetic studies have pinpointed risk variants in genes including GNAI2 and a hyaluronidase gene in US Golden Retrievers. Yet until now, no epidemiological study had specifically characterised MCT frequency, clinical features and survival within the breed in the United States. The GRLS, a prospective cohort of 3,044 Golden Retrievers enrolled between June 2012 and April 2015 and balanced by sex across five geographic regions, offered a uniquely powerful opportunity. Dogs were followed annually with owner and veterinarian questionnaires, biological samples and a dedicated biopsy submission pathway, with histopathology reviewed by two blinded veterinary pathologists. The study’s primary cancer endpoints include haemangiosarcoma, lymphoma, osteosarcoma and high-grade MCT, with high grade defined as Patnaik grade 3 or Kiupel high.

The headline numbers are striking. Of the 3,044 dogs, 164, or 5.39 percent, were diagnosed with a total of 234 mast cell tumours, yielding an incidence rate of 5.58 per 1,000 dog years at risk. A lifetable analysis revealed that young dogs were rarely affected: 99.1 percent of the cohort reached five years of age without an MCT diagnosis. Annual incidence risk peaked at 1.39 percent in dogs aged greater than eight to nine years, before declining in the oldest age groups. The authors note that this decline mirrors patterns seen in other veterinary and even human cancers, where incidence falls in extreme old age, possibly reflecting cellular senescence, stem cell exhaustion or a cancer-resistant phenotype, though diagnostic bias in geriatric patients may also contribute.

Compared with incidence figures from a mixed-breed insured population in Sweden, the Golden Retriever rate appears up to tenfold higher, which the researchers interpret as evidence of a genuine and substantial breed predisposition rather than an artefact of geography or study design. The practical message for owners is clear: vigilance for skin masses, particularly as dogs enter middle and older age, is warranted, and any new lump should prompt veterinary investigation rather than a wait-and-see approach. The median age at first diagnosis in the cohort was just over eight years.

The tumours themselves were predominantly low grade. Cutaneous tumours accounted for 70.5 percent of events and subcutaneous tumours for 16.7 percent, with the remainder being metastatic entries, mucosal or visceral primaries, or digital masses. The most common anatomical locations were the torso, limbs and head and neck, consistent with distributions reported in multi-breed populations. Histopathological grading was available for nearly all cutaneous tumours, and the most frequent grade was the intermediate-low P2KL category. Overall, only 47 of the 234 tumours, or 20.1 percent, met the study’s high-grade definition, a proportion consistent with previous reports of 22 to 26 percent high-grade disease in broader populations. Notably, the findings do not support earlier suggestions that Golden Retrievers are disproportionately prone to high-grade tumours.

Recurrence and spread were comparatively uncommon. Most dogs, 84.2 percent, had a solitary tumour, while 15.9 percent developed new de novo masses at distinct sites, with a median interval of 368 days between the first and subsequent tumours. Local recurrence occurred in just under five percent of cases, and documented metastasis in 9.8 percent, most often to lymph nodes. Critically, every dog with metastatic disease had at least one high-grade tumour; no dog with only low-grade MCTs was found to have spread. The authors suggest this could influence clinical staging recommendations, since extensive staging appears to have low diagnostic yield in low-risk patients, although the absence of standardised staging protocols means some metastases may have gone undetected.

The survival analysis produced the study’s most reassuring result. Median lifespan was 11.68 years in dogs diagnosed with MCT and 11.75 years in the remaining cohort, a difference that was not statistically significant. Median survival time from first MCT diagnosis to death from any cause was 1,367 days, and only 19 dogs, or 11.6 percent, had MCT recorded as their cause of death. Overall survival probabilities after diagnosis were 81.7 percent at one year, 70.0 percent at two years and 40.6 percent at five years. When the analysis was stratified, however, the prognostic weight of tumour biology became evident: the presence of metastasis, a high histological grade, or local recurrence were each associated with statistically significantly reduced survival, while the development of additional de novo tumours was not. Nearly 90 percent of the dogs that died from their disease had at least one high-grade tumour.

The researchers acknowledge several limitations. Cohort recruitment relied on word-of-mouth and snowball sampling, dogs were required to have three-generation pedigrees, and participating owners were highly engaged, with subsidised histopathology likely boosting diagnostic rates relative to the wider population. Treatment details were largely unavailable, precluding analysis of therapeutic impact, and the number of MCT-related deaths was too small for multivariable modelling. Nevertheless, the study’s general-practice setting gives it a realism that insurance-claim and referral-based studies lack. Its overall message is one of measured optimism: for most Golden Retrievers, a mast cell tumour diagnosis is not life-limiting, low-grade disease carries an excellent prognosis with prompt and appropriate management, and the findings justify early investigation and treatment of skin masses rather than fatalism. As the GRLS cohort continues to yield data, it is cementing its role as one of the most valuable resources in comparative oncology, with implications that may ultimately extend to human mast cell disorders and cancer research more broadly.

Subject of Research: Epidemiology, clinical features and survival of mast cell tumours in Golden Retrievers enrolled in the Golden Retriever Lifetime Study

Article Title: Mast cell tumours in the Golden Retriever Lifetime Study: a cohort study assessing frequency, clinical features and survival

Article References: Stratton, Z. V., Brodbelt, D. C., Guillén, A., O’Neill, D. G., Labadie, J., Swafford, B., & Taylor, C. (2026). Mast cell tumours in the Golden Retriever Lifetime Study: a cohort study assessing frequency, clinical features and survival. Veterinary Oncology, 3(1), Article 10. https://doi.org/10.1186/s44356-026-00060-9

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00060-9

Keywords: Golden Retriever, mast cell tumour, canine cancer, veterinary oncology, Golden Retriever Lifetime Study, dog lifespan, histological grading, Kiupel, Patnaik, metastasis, incidence, survival analysis

The trial enrolled 620 patients with previously untreated metastatic non-small cell lung cancer, each confirmed to have a PD-L1 tumor proportion score of at least 50 percent, a threshold that generally predicts strong responsiveness to immune checkpoint inhibitors. Patients with EGFR, ALK or ROS1 alterations were excluded, since those molecular subgroups are typically managed with targeted therapies rather than immunotherapy alone. Participants were randomized to receive either the investigational combination or pembrolizumab by itself. In the experimental arm, sacituzumab govitecan was administered at a dose of 10 mg/kg intravenously on days 1 and 8 of each cycle, alongside pembrolizumab at 200 mg on day 1 of every 21-day cycle. The study was open-label, and its dual primary endpoints were progression-free survival as assessed by blinded independent central review and overall survival.

The efficacy data revealed a pattern that has become familiar in oncology trials that miss their primary goals: encouraging numerical trends that ultimately fail the test of statistical rigor. Median progression-free survival by blinded independent central review was 11.8 months for patients receiving the combination, compared with 7.7 months for those receiving pembrolizumab alone, corresponding to a hazard ratio of 0.81 with a 95 percent confidence interval of 0.66 to 1.00 and a P value of 0.0252. Although patients on the combination lived a median of roughly four months longer without their disease progressing, the result did not cross the prespecified threshold for statistical significance that the trial design demanded.

The interim overall survival analysis was even less encouraging. Median overall survival was 21.5 months in the sacituzumab govitecan plus pembrolizumab arm versus 22.8 months with pembrolizumab alone, yielding a hazard ratio of 1.07 with a 95 percent confidence interval of 0.85 to 1.35 and a P value of 0.7155. In other words, the addition of the antibody-drug conjugate produced no survival advantage at this stage of analysis, and the point estimate actually leaned slightly in favor of monotherapy. For a field in which overall survival remains the ultimate benchmark, that finding will weigh heavily on any decision about whether the combination deserves a place in clinical practice.

Secondary measures of tumor response told a somewhat more favorable story. The confirmed objective response rate was 55.6 percent for the combination compared with 43.7 percent for pembrolizumab alone, meaning a substantially larger share of patients experienced meaningful tumor shrinkage when the antibody-drug conjugate was added. The disease control rate, reported in the study table, was 83.3 percent versus 73.1 percent, respectively. Yet the duration of those responses was nearly identical between the arms, with a median duration of response of 21.4 months for the combination and 21.3 months for pembrolizumab alone. The pattern suggests that while the combination could induce responses in more patients, it did not make the responses that occurred last any longer.

Safety findings added another layer of complexity to the interpretation. Treatment-related adverse events occurred in 93.2 percent of patients receiving the combination compared with 65.4 percent of those on pembrolizumab alone. More strikingly, grade 3 or higher treatment-related adverse events affected 55.7 percent of patients in the combination arm versus 16.5 percent in the monotherapy arm, a more than threefold increase in severe toxicity. The most common treatment-related adverse events in the combination arm included anemia, alopecia, neutropenia, diarrhea and nausea, a profile consistent with the known toxicity signature of sacituzumab govitecan. Investigators reported that the safety profile was consistent with the known profiles of the individual agents, with no new or additional toxicities observed when the two drugs were given together.

Giannis Mountzios, M.D., of the Henry Dunant Hospital Center in Athens, Greece, who presented the findings, acknowledged the tension embedded in the data. While the combination of sacituzumab govitecan and pembrolizumab produced a numerically longer progression-free survival and a higher response rate, he noted, EVOKE-03/KEYNOTE-D46 did not meet statistical significance for its primary progression-free survival endpoint, and overall survival was not significantly improved at this interim analysis. He emphasized that these findings provide important information as the field continues to evaluate treatment strategies for patients with PD-L1-high metastatic non-small cell lung cancer, framing the negative result as a contribution to knowledge rather than simply a failed experiment.

The scientific rationale behind the trial was compelling enough to justify a large Phase 3 investment. Sacituzumab govitecan links a topoisomerase I inhibitor payload to an antibody targeting TROP-2, a protein widely expressed on many epithelial cancers, including a substantial proportion of non-small cell lung tumors. The drug has already secured regulatory approvals in previously treated metastatic settings, and combining antibody-drug conjugates with immune checkpoint inhibitors has become one of the most active areas of clinical research, based on the hypothesis that chemotherapy payload-induced tumor cell death can release antigens and render tumors more visible to the immune system. Pembrolizumab, an anti-PD-1 antibody, is the established first-line standard for metastatic non-small cell lung cancer with PD-L1 tumor proportion scores of 50 percent or greater when no targetable alterations are present.

Dr. Mountzios concluded that, despite a numerical improvement in progression-free survival and a higher response rate, sacituzumab govitecan plus pembrolizumab did not meet statistical significance for progression-free survival compared with pembrolizumab monotherapy in patients with untreated PD-L1-high metastatic non-small cell lung cancer, and that overall survival also did not meet statistical significance at the interim analysis. The results leave pembrolizumab monotherapy in its longstanding position as the reference standard for this population, while raising difficult questions about whether the modest numerical gains in progression-free survival justify the substantially higher toxicity burden and the absence of any demonstrated survival benefit. For now, the trial stands as a reminder that in modern oncology, promising biology and early signals do not guarantee success when subjected to the discipline of a randomized Phase 3 test.

The International Association for the Study of Lung Cancer, founded in 1974, is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies, with a membership of more than 10,000 lung cancer specialists across all disciplines in over 100 countries. The association publishes the Journal of Thoracic Oncology and convenes the World Conference on Lung Cancer, the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, which attracts nearly 7,000 researchers, physicians and specialists from more than 100 countries each year. The conference serves as the venue where pivotal trial results such as EVOKE-03/KEYNOTE-D46 are first unveiled, shaping treatment guidelines and research agendas worldwide. As the oncology community digests these findings, attention will turn to whether further analyses, biomarker-driven subgroup explorations or alternative combination strategies can eventually translate the promise of antibody-drug conjugates into durable first-line benefits for patients with advanced lung cancer.

Subject of Research: Phase 3 testing of sacituzumab govitecan plus pembrolizumab versus pembrolizumab monotherapy as first-line treatment for PD-L1-high metastatic non-small cell lung cancer

Article Title: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

Article References: Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: sacituzumab govitecan, pembrolizumab, non-small cell lung cancer, PD-L1, EVOKE-03, KEYNOTE-D46, antibody-drug conjugate, immunotherapy, progression-free survival, overall survival, Phase 3 trial, IASLC

Copper is an indispensable trace element, serving as a cofactor for enzymes involved in respiration, antioxidant defense, and connective tissue formation. Yet when copper homeostasis collapses, the consequences for a cell can be fatal in a way that scientists only began to define in 2022. That year, Peter Tsvetkov and colleagues reported in Science that excess mitochondrial copper binds directly to lipoylated components of the tricarboxylic acid cycle, the enzymatic engine at the heart of mitochondrial metabolism. The resulting accumulation of lipoylated TCA cycle proteins triggers a distinctive form of proteotoxic stress that the authors named cuproptosis, setting it apart from apoptosis, necrosis, and other better-known death programs. Crucially, the process depends on the mitochondrial protein ferredoxin 1, or FDX1, which regulates protein lipoylation through its interaction with the lipoic acid synthase LIAS.

What makes this mechanism so intriguing for liver cancer is a biological paradox. Hepatocellular carcinoma cells frequently exhibit elevated copper metabolism, importing and distributing the metal aggressively to fuel their proliferative demands. But the same dependence appears to raise their vulnerability: when copper overload is pharmacologically forced into the mitochondria, these copper-hungry cells die disproportionately. Earlier work from Tsvetkov’s group had shown that highly lipoylated, mitochondria-rich tumors are especially sensitive to elesclomol, an investigational copper ionophore that ferries copper ions into the mitochondrial interior. Disulfiram, an old alcohol-aversion drug that acts as a copper ionophore, has shown similar copper-dependent toxicity against tumor cells in multiple preclinical models, and recent studies have linked DLAT, a lipoylated enzyme of the pyruvate dehydrogenase complex, to elesclomol sensitivity specifically in hepatocellular carcinoma.

The iron side of the equation is equally consequential. Ferroptosis, first described in 2012, is a form of regulated cell death driven by iron-dependent lipid peroxidation. When the antioxidant systems that normally reduce lipid hydroperoxides falter, particularly the glutathione–glutathione peroxidase 4, or GSH–GPX4, axis, polyunsaturated fatty acids in cellular membranes undergo a radical chain reaction that ruptures the lipid bilayer. The liver, as the body’s principal iron storage and metabolic organ, is exquisitely sensitive to this chemistry. Hepatocellular carcinoma cells, meanwhile, must constantly manage iron influx and oxidative stress to survive, and numerous studies have documented that manipulating iron availability, lipid composition, and antioxidant capacity can tip these cells into ferroptotic death.

The review pays particular attention to the regulatory networks that determine how sensitive a given hepatocellular carcinoma cell is to ferroptosis. Nuclear factor erythroid 2–related factor 2, or NRF2, a master transcriptional regulator of antioxidant responses, emerges as a central node. When NRF2 signaling is active, cells upregulate glutathione synthesis, iron efflux, and a battery of cytoprotective enzymes, effectively raising a shield against lipid peroxidation. FSP1, a ferroptosis suppressor protein that reduces coenzyme Q10 at the plasma membrane, provides a parallel rescue pathway that operates independently of glutathione. Both defenses can be subverted: work from Ren and colleagues showed that overcoming the compensatory elevation of NRF2 rendered hepatocellular carcinoma cells markedly more vulnerable to disulfiram/copper-induced ferroptosis, while other studies have demonstrated that blocking the cystine transporter xCT, which feeds glutathione synthesis, cooperates lethally with copper-driven stress.

It is at this intersection that the review’s central thesis emerges. Copper toxicity and ferroptosis are not isolated programs; they converge on shared metabolic vulnerabilities. Mitochondrial copper overload destabilizes iron-sulfur clusters, the ancient cofactors that support respiratory and repair enzymes, and this destabilization can itself sensitize cells to lipid peroxidation through iron regulatory proteins. More strikingly, glutathione sits at the crossroads of both pathways. The antioxidant tripeptide neutralizes copper-driven oxidative stress on one hand and fuels GPX4-mediated suppression of ferroptosis on the other. Experimental studies in primary liver cancer have shown that ferroptosis inducers enhance cuproptosis triggered by copper ionophores, and that disulfiram/copper treatment consumes glutathione in a way that launches what one team described as a cascade of ferroptosis and cuproptosis when xCT compensation is simultaneously blocked.

The therapeutic implications are substantial. Standard first-line drugs for advanced hepatocellular carcinoma, including sorafenib and lenvatinib, already exert part of their activity through ferroptosis-related mechanisms; lenvatinib, for example, has been shown to induce ferroptosis via fibroblast growth factor receptor-4 inhibition, while sorafenib sensitivity is modulated by metallothioneins and antioxidant pathways. Layering copper ionophores on top of these agents could push tumor cells past a metabolic tipping point that single-agent therapy never reaches. Nanotechnology is accelerating this vision: research groups have developed reactive oxygen species–responsive nanoparticles co-delivering elesclomol and copper together with anti–PD-L1 immunotherapy, as well as injectable hydrogel systems that combine cuproptosis induction with stemness inhibition to overcome lenvatinib resistance. A 2026 study in Antioxidants described a ROS-responsive nanoplatform that targets both cuproptosis and ferroptosis for synergistic therapy against hepatocellular carcinoma, illustrating how rapidly the dual-targeting concept is moving from theory toward experimental implementation.

The tumor microenvironment adds a further dimension of complexity, and opportunity. Both cuproptosis and ferroptosis are immunologically loud forms of cell death: dying cells release damage-associated molecular patterns and oxidized lipids that can stimulate antitumor immunity, and vaccination with early ferroptotic cancer cells has been shown to induce efficient antitumor immune responses. Multiomics and single-cell sequencing analyses have linked cuproptosis signatures to the immunosuppressive architecture of tumors, while ferroptotic tumor cells can enhance the efficacy of checkpoint inhibitors. Yet the picture is not uniformly favorable. Some work has found that disulfiram combined with copper stabilizes PD-L1 in hepatocellular carcinoma, potentially inducing immunosuppression, a reminder that metal-based therapies must be calibrated carefully if they are to synergize with, rather than undermine, immunotherapy. Macrophage polarization, exosome-mediated signaling, and the metabolic state of stromal cells all modulate how these death programs play out in vivo.

The review’s authors are candid about the limits of the current evidence. Direct clinical data demonstrating that pharmacological induction of cuproptosis, or coordinated cuproptosis–ferroptosis targeting, benefits patients with hepatocellular carcinoma are still lacking. Copper chelation trials, trientine-based antiangiogenic strategies, and disulfiram repurposing efforts have generated encouraging preclinical signals, but translating them into validated regimens will require careful attention to dosing, copper delivery, and patient selection. Biomarkers are an urgent need: serum copper, zinc, and metallothionein levels have been proposed as potential biomarkers for hepatocellular carcinoma, and gene-expression signatures built around FDX1, DLAT, ATP7A, and other cuproptosis-related genes are being explored for prognostic and predictive value. Determining which tumors are copper-vulnerable, which rely on NRF2 or FSP1 for ferroptosis resistance, and which harbor metabolic contexts that favor one death program over the other will be essential for rational combination therapy.

Even with these caveats, the synthesis marks a conceptual shift in how liver cancer might be treated. Rather than viewing copper and iron merely as nutrients that tumors consume, the field increasingly regards their homeostatic control as a pair of interlocking kill switches. Disrupting mitochondrial copper handling destabilizes the metabolic core of the cell; dismantling antioxidant defenses unleashes iron-catalyzed membrane destruction; and because glutathione and related systems guard against both threats simultaneously, a single well-designed intervention can pull two levers at once. With combination strategies already showing synergy in preclinical liver cancer models, and nanoparticle delivery platforms maturing quickly, the copper–iron crosstalk framework offers hepatocellular carcinoma research one of its most mechanistically grounded and therapeutically tantalizing frontiers in years.

Subject of Research: Cuproptosis and ferroptosis as coordinated therapeutic targets in hepatocellular carcinoma

Article Title: Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma

Article References: Xie, X., Cao, H., Chen, H., Zhang, S., & Han, Z. (2026). Harnessing copper-iron crosstalk: A novel strategy to combat hepatocellular carcinoma. Medical Oncology, 43(10), Article 268. https://doi.org/10.1007/s12032-026-03399-z

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03399-z

Keywords: cuproptosis, ferroptosis, hepatocellular carcinoma, copper metabolism, iron metabolism, GPX4, NRF2, FDX1, disulfiram, elesclomol, glutathione, targeted therapy

The scale of the prostate cancer problem in Brazil is considerable. According to estimates from the country’s National Cancer Institute, prostate cancer is the most frequently diagnosed malignancy among Brazilian men when non-melanoma skin cancers are excluded, with nearly 78,000 new cases expected annually in the coming years. Globally, roughly 1.4 million new cases and more than 375,000 deaths were estimated in 2020, ranking prostate cancer as the second most frequently diagnosed cancer and the fifth leading cause of cancer death among men. Yet while high-income countries have accumulated extensive survival data, low- and middle-income countries such as Brazil have historically lacked robust, registry-based studies linking patient characteristics to long-term outcomes, a gap the new research set out to close.

To build the cohort, the team tapped the Hospital Cancer Registry of Espírito Santo, an institutional system recognized by the International Agency for Research on Cancer, and linked its records with the national Mortality Information System. Record linkage relied on key identifying variables including patient name, mother’s name, date of birth, sex and municipality of residence, with phonetic Soundex encoding applied to name fields to improve matching accuracy. Only records showing exact agreement across the selected identifiers were retained, and every matched pair was manually reviewed using complementary information such as residential address and dates of diagnosis and death. Patients were followed from diagnosis until death from any cause or administrative censoring at the end of 2021, producing a follow-up window that spans more than two decades of clinical care.

The demographic and clinical profile of the cohort reveals much about the population the Brazilian public health system serves. The average age at diagnosis was 69.2 years, and 70.39 percent of patients were 65 or older. Nearly two-thirds of the men identified as non-White, 65.92 percent were married, and almost two-thirds had no formal education or only basic schooling. The overwhelming majority of tumors, 98.52 percent, were adenocarcinomas, and 91.65 percent of patients had no distant metastases at diagnosis. First treatments were distributed across surgery in 23.71 percent of cases, hormone therapy in 21.97 percent, radiotherapy in 19.47 percent and combined radiotherapy and hormone therapy in 15.15 percent. By the end of follow-up, 18.34 percent of patients had died from prostate cancer and 21.14 percent had died from other causes, a pattern that underscores the importance of accounting for competing causes of death in elderly cancer populations.

Methodologically, the study is notable for the care with which it separates two distinct statistical questions. Because many of these older patients died of causes unrelated to their cancer, the researchers used cause-specific Cox proportional hazards models to estimate the instantaneous hazard of prostate cancer death among men who remained at risk, rather than the competing-risk Fine–Gray framework the same team had previously applied to this cohort. The authors emphasize that the two approaches answer complementary questions: Fine–Gray models estimate the cumulative probability of cancer-specific death in the presence of competing mortality, while cause-specific Cox models are better suited to etiological inference and the identification of prognostic determinants. Kaplan–Meier curves, which treated other-cause deaths as censored observations, were used only descriptively, since they can overestimate cumulative cancer-specific mortality when competing events are frequent.

The univariate survival analyses told a striking story. Five-year prostate cancer-specific survival fell from 92.3 percent in men diagnosed before age 65 to 85.7 percent in those diagnosed at 65 or older. Survival dropped steeply with advancing tumor stage, from 96.5 percent for stage I disease to just 49.9 percent for stage IV, and the presence of distant metastases cut five-year survival to 42.5 percent, less than half the 91.7 percent seen in patients without metastatic spread. Patients who underwent surgery or radiotherapy as initial treatment showed five-year survival above 95 percent, while those receiving hormone therapy had markedly lower survival at 77.4 percent. Education also mattered: men with no formal education had five-year survival of 83.4 percent, compared with 90.7 percent among those with middle or high education.

When the researchers adjusted for multiple factors simultaneously in a multivariable Cox model restricted to 6,481 patients with complete data, several independent predictors of prostate cancer-specific mortality emerged. Each additional decade of age at diagnosis raised the hazard of prostate cancer death by 14 percent. Education showed a clear protective gradient, with basic education associated with an 18 percent lower risk and middle or high education a 36 percent lower risk compared with no formal schooling. Patients referred from private or insurance-based services rather than the public Unified Health System had a modestly higher risk of prostate cancer-specific death, a finding the authors note warrants careful interpretation. Surgery was associated with a substantially lower hazard of death, while hormone therapy was associated with nearly double the risk.

The authors are careful to caution that the treatment associations should not be read as causal effects. In real-world oncology, patients selected for surgery or radiotherapy typically have localized disease and preserved functional status, whereas hormone therapy is generally reserved for more advanced disease. This confounding by indication is compounded in the study by a substantial proportion of missing data: TNM staging was absent for 48.92 percent of records and disease status after first treatment was missing for 51.71 percent, which prevented these key severity variables from entering the adjusted models. A sensitivity analysis comparing the complete-case sample with excluded patients, using standardized mean differences, found negligible imbalance for core variables such as age, race, marital status and metastasis status, suggesting the complete-case analysis was unlikely to have introduced major selection bias, though residual confounding cannot be excluded.

The findings carry clear public health implications for Brazil and other middle-income countries. Lower educational attainment is associated with delayed diagnosis and treatment, reduced chances of cure and higher mortality, likely reflecting gaps in health information, access and understanding of symptoms. The study’s authors argue that strengthening early diagnosis, reducing social inequalities in access to care and improving the quality and completeness of clinical data in cancer registries are essential steps toward better outcomes. They also highlight the value of applying complementary statistical frameworks to the same population, noting that competing-risk models support population-level risk prediction while cause-specific models illuminate etiological relationships. Together, the two analyses of the Espírito Santo cohort offer a more complete picture of prostate cancer prognosis in Brazil than either method alone, and provide a template for how registry-linked data can drive evidence-based cancer policy in resource-constrained settings.

Subject of Research: Prognostic factors for prostate cancer-specific survival and mortality in a large retrospective Brazilian cohort

Article Title: Survival and Mortality Predictors in Prostate Cancer: A Retrospective Cohort of 10 556 Brazilian Patients

Article References: Survival and Mortality Predictors in Prostate Cancer: A Retrospective Cohort of 10 556 Brazilian Patients. (n.d.). https://doi.org/10.1002/cnr2.70667

Image Credits: AI Generated

DOI: 10.1002/cnr2.70667

Keywords: prostate cancer, survival analysis, Brazil, cancer registry, Cox regression, competing risks, health inequalities, hormone therapy, education level, mortality predictors, Espírito Santo, oncology

The phenomenon is called lineage infidelity, and it describes a form of cellular plasticity in which small-cell lung cancer cells transition between molecularly distinct states to evade both physiological pressures and therapeutic attack. Historically, the disease was viewed as a single, uniform neuroendocrine tumor. Modern genomic and transcriptomic profiling has dismantled that view entirely, revealing at least four major molecular subtypes defined by the dominant activity of key transcription factors: ASCL1 in the SCLC-A subtype, NEUROD1 in SCLC-N, POU2F3 in SCLC-P, and YAP1 marking a mesenchymal-like, non-neuroendocrine phenotype often called SCLC-Y. The status of YAP1 as a true lineage-defining factor remains debated among researchers, but its value as a marker of therapeutic escape is widely accepted.

Crucially, these states are not fixed. They represent fluid points along a phenotypic spectrum, allowing tumors to shift identities as conditions change. A tumor that begins as a highly neuroendocrine SCLC-A malignancy may transition toward a non-neuroendocrine or inflamed state when treatment targets its original vulnerabilities, effectively changing molecular camouflage mid-course. Single-cell RNA sequencing and genetically engineered mouse models have been instrumental in mapping these transitions, showing that they are governed less by new mutations and more by an epigenetic rheostat—a dynamic, reversible control system of gene expression built on chromatin remodeling and lineage-specific enhancers.

The mechanistic details are striking. The best-characterized switch occurs between the SCLC-A and SCLC-N states, both neuroendocrine but occupying distinct regulatory territories. Activation of NOTCH signaling induces the expression of HES1, which directly represses ASCL1, facilitating movement toward NEUROD1-positive or non-neuroendocrine phenotypes. In SCLC-A cells, ASCL1 acts as a pioneer factor keeping chromatin accessible at its target genes; when epigenetic co-factors such as LSD1 are perturbed, methylation marks at H3K4 and H3K9 change, effectively erasing the cell’s transcriptional memory and opening the door to alternative identities. MYC amplification can drive further progression, pushing cells from ASCL1-dominant states through NEUROD1-high states and ultimately toward YAP1-driven mesenchymal phenotypes.

Perhaps the most clinically consequential observation concerns the SCLC-I, or inflamed, subtype, which recent evidence suggests may be a common evolutionary endpoint for tumors treated with chemotherapy. This transition involves a global decrease in DNA methylation that activates endogenous retroviruses and triggers interferon signaling, supporting the shift toward an inflamed phenotype. Meanwhile, the tumor microenvironment supplies external cues that flip internal switches: hypoxia within the tumor core stabilizes HIF-1α, which downregulates neuroendocrine markers and promotes a migratory, mesenchymal-like state. Chemotherapy itself, beyond killing sensitive clones, induces stress responses that can push surviving cells into quiescent or variant states—raising the uncomfortable possibility that standard care may inadvertently steer tumors toward more recalcitrant identities.

But the review’s authors argue that this plasticity is not merely a survival strategy; it is also a weapon clinicians can turn against the tumor. Because every lineage transition opens a new window of vulnerability, they propose a ‘Push-and-Pull’ strategy of evolutionary steering. In the ‘Push’ phase, epigenetic modifiers such as LSD1 inhibitors destabilize the dominant lineage, inducing ASCL1-high neuroendocrine cells to lose their identity and transition toward a more inflamed or non-neuroendocrine state. In the ‘Pull’ phase, a second agent lethally targets the newly acquired state. If the Push produces an inflamed SCLC-I phenotype, the Pull would be immune checkpoint blockade, which is significantly more effective in that molecular context.

Subtype-specific vulnerabilities provide the ammunition for the Pull. Tumors transitioning from SCLC-A/N states toward SCLC-P develop a profound dependence on the DNA damage response, driven by replication stress from MYC or POU2F3 activity, making them hypersensitive to PARP and ATR inhibitors. Cells adopting a YAP1-high mesenchymal phenotype often upregulate the surface marker TROP2, and clinical trials are now investigating TROP2-targeted antibody-drug conjugates for patients whose tumors have undergone this transition—effectively converting a resistance mechanism into a delivery system for chemotherapy. Epigenetic agents such as HDAC or EZH2 inhibitors may even reset the chromatin landscape of resistant non-neuroendocrine cells, reverting them to a neuroendocrine state in which they regain sensitivity to original platinum regimens, a concept known as chemo-resensitization.

Implementing these strategies in the clinic is far from straightforward. Small-cell lung cancer rarely exists as a single pure subtype; high-resolution single-cell mapping shows that most clinical samples are composite tumors containing multiple subtypes in varying proportions. Treating the dominant clone often triggers explosive expansion of a pre-existing minor subclone, and distinguishing clonal selection from true transdifferentiation is essential, because the two demand different interventions. Real-time monitoring is therefore central to the entire framework: longitudinal analysis of circulating tumor DNA and circulating tumor cells can detect molecular signatures of a subtype switch—such as rising POU2F3 or YAP1 fragments, or shifts in subtype-specific DNA methylation patterns—months before imaging reveals tumor growth, allowing preemptive therapeutic pivots while disease burden remains low.

Pharmacological hurdles compound the challenge. HDAC inhibitors like vorinostat and EZH2 inhibitors like tazemetostat are FDA-approved for other malignancies, but their efficacy in small-cell lung cancer remains confined to early-phase trials. LSD1 inhibitors such as iadademstat have shown early promise but are not yet standard of care. Concurrent administration of epigenetic Push agents and cytotoxic Pull agents often produces prohibitive toxicities, including severe myelosuppression and gastrointestinal distress, because chromatin modifiers exert broad transcriptional effects. Sequential targeting mitigates toxicity but demands precise, validated liquid biopsy biomarkers that do not yet fully exist in clinical form. Overcoming these barriers, the authors suggest, will require more selective epigenetic tools such as PROTACs and dynamic trial designs that use ctDNA to trigger therapy switches before relapse becomes visible.

What emerges from this synthesis is a fundamentally new vision for treating one of medicine’s deadliest cancers. Rather than reacting to resistance after it appears, oncologists of the future may proactively direct tumor trajectories toward therapeutic dead ends—luring cancer cells into states where their acquired vulnerabilities become lethal traps. Preclinical platforms including genetically engineered mouse models, patient-derived xenografts, and organoids are already providing the testing grounds for such interventions, and precision immunotherapy approaches aim to extend the benefits of immune checkpoint inhibitors to cold tumors through epigenetic priming. If the capacity for change is the tumor’s greatest strength, the reviewers contend, it may also prove to be its ultimate undoing—transforming small-cell lung cancer from a recalcitrant malignancy into a disease that is manageable, and perhaps one day curable.

Subject of Research: Lineage infidelity and subtype plasticity driving chemoresistance in small-cell lung cancer

Article Title: Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilities

Article References: Ajeh, I. J., Ikukpla’si, O. S. I., Bisoye, D. A., & Danraka, A. (2026). Lineage infidelity in small-cell lung cancer: driving subtype transitions and acquired therapeutic vulnerabilities. Clinical Cancer Bulletin, 5(1), Article 9. https://doi.org/10.1007/s44272-026-00061-7

Image Credits: AI Generated

DOI: 10.1007/s44272-026-00061-7

Keywords: small-cell lung cancer, lineage infidelity, ASCL1, NEUROD1, POU2F3, YAP1, epigenetic reprogramming, tumor plasticity, chemoresistance, Push-and-Pull strategy, liquid biopsy, immune checkpoint blockade